Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

[Triglyceride (TG) and remnant lipoproteins].

Yoshida H, Kisugi R, Koike M, Kurosawa H.

Rinsho Byori. 2012 Apr;60(4):343-8. Japanese.

PMID:
22686044
3.

Remnant lipoprotein cholesterol homogenous assay (RemL-C) is closely associated with very-low-density lipoprotein remnants: comparison with the immunoseparation assay.

Nagashima M, Mori Y, Morita R, Takada M, Lee S, Taira T, Miyauchi K, Kuwata H, Kayahara N, Hirano T.

Rinsho Byori. 2008 Nov;56(11):973-9.

PMID:
19086452
4.

Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.

Marcoux C, Tremblay M, Fredenrich A, Davignon J, Cohn JS.

Metabolism. 2001 Jan;50(1):112-9.

PMID:
11172484
5.
7.

Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study.

Imke C, Rodriguez BL, Grove JS, McNamara JR, Waslien C, Katz AR, Willcox B, Yano K, Curb JD.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1718-22. Epub 2005 Jun 9.

8.

Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients.

Schreier L, González AI, Elbert A, Berg G, Wikinski R.

Metabolism. 2004 Aug;53(8):1013-5.

PMID:
15281010
9.

The role of non-LDL:non-HDL particles in atherosclerosis.

Segrest JP.

Curr Diab Rep. 2002 Jun;2(3):282-8. Review.

PMID:
12643186
10.

Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C).

Yoshida H, Kurosawa H, Hirowatari Y, Ogura Y, Ikewaki K, Abe I, Saikawa S, Domitsu K, Ito K, Yanai H, Tada N.

Lipids Health Dis. 2008 May 17;7:18. doi: 10.1186/1476-511X-7-18.

11.
12.

Adjustment of direct high-density lipoprotein cholesterol measurements according to intercurrent triglyceride corrects for interference by triglyceride-rich lipoproteins.

Perera NJ, Burns JC, Perera RS, Lewis B, Sullivan DR.

J Clin Lipidol. 2010 Jul-Aug;4(4):305-9. doi: 10.1016/j.jacl.2010.04.002. Epub 2010 Apr 22.

PMID:
21122664
13.

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.

Toth PP.

Vasc Health Risk Manag. 2016 May 6;12:171-83. doi: 10.2147/VHRM.S104369. eCollection 2016. Review.

14.

Non-HDL cholesterol as a measure of atherosclerotic risk.

Packard CJ, Saito Y.

J Atheroscler Thromb. 2004;11(1):6-14. Review.

15.

Atherogenicity of triglyceride-rich lipoproteins.

Krauss RM.

Am J Cardiol. 1998 Feb 26;81(4A):13B-17B.

PMID:
9526808
16.

Postprandial lipoprotein responses in hypertriglyceridemic subjects with and without cardiovascular disease.

Hughes TA, Elam MB, Applegate WB, Bond MG, Hughes SM, Wang X, Tolley EA, Bittle JB, Stentz FB, Kang ES.

Metabolism. 1995 Aug;44(8):1082-98.

PMID:
7637651
17.

[Cutting-edge research on the metabolism of remnant lipoproteins].

Yamamura T, Ishigami M.

Rinsho Byori. 2010 Jun;58(6):613-21. Review. Japanese.

PMID:
20662274
18.

Properties of triglyceride-rich and cholesterol-rich lipoproteins in the remnant-like particle fraction of human blood plasma.

Campos E, Kotite L, Blanche P, Mitsugi Y, Frost PH, Masharani U, Krauss RM, Havel RJ.

J Lipid Res. 2002 Mar;43(3):365-74.

19.

Atherogenic lipoproteins in end-stage renal disease.

Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S30-3. Review.

PMID:
11576918
20.

Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.

Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ.

J Am Soc Nephrol. 2001 Feb;12(2):341-8.

Supplemental Content

Support Center